Intraosseous Spindle Cell Rhabdomyosarcoma with MEIS1::NCOA2 Fusion – Case Report with Substantial Clinical Follow-up and Review of the Literature

Abstract

Spindle cell/sclerosing rhabdomyosarcoma (SSRMS) is a clinicopathologically and molecularly heterogeneous disease. Gene fusions have been identified in intraosseous SSRMS, consisting predominantly of EWSR1/FUS::TFCP2 and MEIS1::NCOA2. The former often follow an aggressive clinical course; there is limited clinical follow-up available for the latter. We report here a new case of the very rare intraosseous SSRMS with MEIS1::NCOA2 gene fusion and include the detailed treatment course and 52 months of clinical follow-up. SSRMS with MEIS1::NCOA2 gene fusion appears biologically distinct from other intraosseous SSRMS, following a course characterized by local recurrence with rare reports of metastasis to date.

Keywords:

• Rhabdomyosarcoma
• bone
• gene fusion
• MEIS1
• NCOA2

View correction statement:

Correction

Disclosure statement

No potential conflict of interest was reported by the author(s).

Correction Statement

This article was originally published with errors, which have now been corrected in the online version. Please see Correction (https://doi.org/10.1080/07357907.2023.2255668)

Additional information

Funding

This research received no specific grant funding.